The diabetes medicine sales in Canada are forecasted to consistently rise from 2024, with a compounded average growth rate that reflects considerable market expansion. In 2024, sales commence at a baseline of 12.6, ultimately reaching 16.4 by 2028. When compared to the previous years, this trend signifies a robust annual growth trend. The double set of values indicates duplication likely due to potential clerical oversight in data representation.
Future trends to watch for include innovations in diabetes treatment, pricing dynamics, and changes in healthcare policy affecting drug accessibility. Additionally, the aging population and increasing diabetes prevalence will be key determinants of market trajectory.
